Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

SMMT earnings analysis

Filed April 30, 2026 · Our reading of the company's report

The latest report

Summit Therapeutics reported a significant net loss of $189.4 million for Q1 2026, exacerbated by rising operational and R&D expenses primarily due to ongoing clinical trials for ivonescimab. Operating expenses rose to…

Read full summary

Summit Therapeutics reported a significant net loss of $189.4 million for Q1 2026, exacerbated by rising operational and R&D expenses primarily due to ongoing clinical trials for ivonescimab. Operating expenses rose to $195.2 million, driven largely by an 83% increase in R&D costs. The company continues to face cash flow challenges with a severe cash burn rate amid ongoing development efforts, leading to substantial concerns about liquidity going forward.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.24

What stood out

  • Revenue Growth Analysis

    Revenue remains undisclosed as of this quarter; however, estimated revenue for Q1 2026 is projected at $40.85 million.

  • Dramatic Increase in Operating Expenses

    Total operating expenses soared to $195.2 million, up 192% year-over-year from $66.8 million in Q1 2025.

  • Significant R&D Investment

    R&D expenses surged by 159% to $132.6 million from $51.2 million year-over-year, reflecting increased clinical trial activities.

  • Cash and Investments Outlook

    As of March 31, 2026, the company reported cash and equivalents of $106.5 million, indicating tightened liquidity.

  • Increased Stock-Based Compensation

    Stock-based compensation soared to $72.8 million, up from $11.1 million in Q1 2025, contributing to higher general and administrative expenses.

  • Clinical Trials Progress

    Enrollment for HARMONi-3 completed in Q1 2026 while the company anticipates further clinical development in advanced NSCLC and CRC.

What to watch

  • High Cash Burn Rate

    Net cash used in operating activities was $122.3 million, raising concerns about sustaining operations long-term.

  • Substantial Doubt about Going Concern

    The cash and equivalents are insufficient to fund operations for the next 12 months without raising additional capital.

  • Dependency on Clinical Trials

    Continued reliance on the clinical success of ivonescimab poses risks as the company lacks FDA approval yet and has incurred heavy expenses.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.